Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Estacion, Mark ^a,b   Waxman, Stephen G ^a,b   Dib Hajj, Sulayman D ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; SODIUM CHANNEL NAV1.7; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE; SCN9A PROTEIN, HUMAN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; ERYTHROMELALGIA; HUMAN; HUMAN CELL; MUTANT; NERVE CELL EXCITABILITY; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SODIUM CURRENT; SPINAL GANGLION; VOLTAGE CLAMP; WILD TYPE; ANGINA PECTORIS; CELL LINE; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

ACETANILIDES; ANGINA PECTORIS; CELL LINE; GANGLIA, SPINAL; HUMANS; MUTATION; PIPERAZINES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 77953124651     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-35     Document Type: Article

References (35)

1. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132(3):237-251. 10.1016/j.pain.2007.08.033, 17920770.
2. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci 2007, 30(11):555-563. 10.1016/j.tins.2007.08.004, 17950472.
3. Waxman SG. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat Neurosci 2007, 10(4):405-409. 10.1038/nn1857, 17387329.
4. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110(8):904-910. 10.1161/01.CIR.0000139333.83620.5D, 1513623, 15302796.
5. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl 4):iv6-iv14. 10.1136/hrt.2005.078790, 1861317, 16775092.
6. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006, 1617037, 16520744.
7. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S169-177. 10.1111/j.1540-8167.2006.00401.x, 1482456, 16686675.
8. Wang GK, Calderon J, Wang SY. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008, 73(3):940-948. 10.1124/mol.107.041541, 2275669, 18079277.
9. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, NaV1.7 and tetrodotoxin-resistant, NaV1.8, Na+ channels by ranolazine. Channels 2008, 2(6):449-460. 10.4161/chan.2.6.7362, 19077543.
10. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation. Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine. Circulation 2007, 2566303, 17785620.
11. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004, 108(3):237-247. 10.1016/j.pain.2003.12.035, 15030943.
12. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008, 64(6):644-653. 10.1002/ana.21527, 19107992.
13. Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 1998, 18(23):9607-9619.
14. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005, 128(Pt 8):1847-1854. 10.1093/brain/awh514, 15958509.
15. Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman SG. Nav1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 2008, 28(43):11079-11088. 10.1523/JNEUROSCI.3443-08.2008, 18945915.
16. Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L, Cao X, Yang Y, Waxman SG. Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain 2009, 132(7):1711-1722. 10.1093/brain/awp078, 19369487.
17. Harty TP, Dib-Hajj SD, Tyrrell L, Blackman R, Hisama FM, Rose JB, Waxman SG. NaV1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J Neurosci 2006, 26(48):12566-12575. 10.1523/JNEUROSCI.3424-06.2006, 17135418.
18. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006, 103(21):8245-8250. 10.1073/pnas.0602813103, 1472458, 16702558.
19. Stamboulian S, Choi J-S, Ahn H-S, Chang Y-W, Tyrrell L, Black J, Waxman S, Dib-Hajj S. ERK1/2 phosphorylates sodium channel Nav1.7 and alters its gating properties. J Neurosci 2010, 30(5):1637-1647. 10.1523/JNEUROSCI.4872-09.2010, 20130174.
20. Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004, 24(38):8232-8236. 10.1523/JNEUROSCI.2695-04.2004, 15385606.
21. Jarecki BW, Sheets PL, Jackson JO, Cummins TR. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J Physiol 2008, 586(Pt 17):4137-4153. 10.1113/jphysiol.2008.154906, 2652197, 18599537.
22. Cheng X, Dib-Hajj SD, Tyrrell L, Wright DE, Fischer TZ, Waxman SG. Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Nav1.7 produce distinct pain disorders. Mol Pain 2010, 6:24. 10.1186/1744-8069-6-24, 2876140, 20429905.
23. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol (Lond) 2003, 551(Pt 3):741-750. 10.1113/jphysiol.2003.047357, 2343279, 12843211.
24. Choi JS, Dib-Hajj SD, Waxman S. Differential slow inactivation and use-dependent inhibition of Nav1.8 channels contribute to distinct firing properties in IB4+ and IB4- DRG neurons. J Neurophysiol 2007, 97(2):1258-1265. 10.1152/jn.01033.2006, 17108087.
25. Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN. Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. J Neurosci 2006, 26(27):7281-7292. 10.1523/JNEUROSCI.1072-06.2006, 16822986.
26. Rush AM, Cummins TR, Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J Physiol (Lond) 2007, 579(Pt 1):1-14. 10.1113/jphysiol.2006.121483, 2075388, 17158175.
27. Dib-Hajj SD, Estacion M, Jarecki BW, Tyrrell L, Fischer TZ, Lawden M, Cummins TR, Waxman SG. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. Mol Pain 2008, 4:37. 10.1186/1744-8069-4-37, 2556659, 18803825.
28. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008, 51(6):581-589. 10.1097/FJC.0b013e3181799690, 18520952.
29. Gould HJ, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol 2009, PMID: 19773645.
30. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116(15):1647-1652. 10.1161/CIRCULATIONAHA.107.724880, 17804441.
31. Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004, 41(3):171-174. 10.1136/jmg.2003.012153, 1735695, 14985375.
32. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52(5):767-774. 10.1016/j.neuron.2006.10.006, 17145499.
33. Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol 2006, 59:553-558. 10.1002/ana.20776, 16392115.
34. Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating. J Biol Chem 2006, 281(47):36029-36035. 10.1074/jbc.M607637200, 17008310.
35. Dib-Hajj SD, Choi JS, Macala LJ, Tyrrell L, Black JA, Cummins TR, Waxman SG. Transfection of rat or mouse neurons by biolistics or electroporation. Nat Protoc 2009, 4(8):1118-1126. 10.1038/nprot.2009.90, 19617884.